Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced an evaluation adjustment, reflecting a complex assessment of its performance and market position. Despite reporting positive quarterly financials, the company faces long-term growth challenges, including declining net sales and operating profit, alongside a cautious approach to shareholder returns.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced an evaluation adjustment reflecting changes in its financial metrics. Key indicators include a P/E ratio of 20, a Price to Book Value of 1.72, and a dividend yield of 2.89%. The company faces challenges in long-term growth despite this revised assessment.

Tasly Pharmaceutical Group Co., Ltd. saw a significant increase in stock price on March 27, 2026, contrasting with the modest gain of the China Shanghai Composite. Despite recent positive trends, the company faces long-term challenges, including declining net sales and a substantial drop in net profit over the past five years.

Tasly Pharmaceutical Group Co., Ltd. faced a significant decline in stock value, dropping 4.45% on March 23, 2026. The company has experienced a 10.52% decrease over the past year, with net sales contracting at an annual rate of 9.48% and a notable drop in net profit and operating cash flow.